You are here

Feb 10, 2015

The project named “Spark”, which is devoted to the development of a drug (IPR19) for the treatment of the cognitive impairment associated with schizophrenia, has obtained a “RETOS-Colaboración” grant from the Ministry of Economy and Competitiveness of Spain (RTC-2014-1645-1).

Jan 16, 2015

Ernest Giralt, co-founder of Iproteos and SAB chairman, together with Laura Nevola, IRB Barcelona research associate, have just published a review entitled “Modulating protein-protein interactions: the potential of peptides”. The article, released today 16th of January on Chemical Communications, covers the latest progress in the use of peptides as therapeutics. Peptides have not been totally exploited as drugs because of their poor in vivo stability and their inappropriate ADME properties.

Jan 13, 2015

Iproteos will participate on the BIO-Europe Spring 2015. This 9th edition will be held next March from Monday 9th to Wednesday 11th in Paris. Over 2000 delegates, representing more than 1,200 companies took part on the previous BIO-Europe Spring conference, which took place in Turin. BIO-Europe events put together biotechs, pharma companies, finance entities, CRO, CMO and others in order to promote industry growth. In this regard, the partnering meetings are crucial to foster collaborations.

Dec 02, 2014

Iproteos has been selected to present at the 8th edition of the European Venture Summit, next 8-9 Dec in Düsseldorf. The EVS is the leading investment event in Europe for the technological start-ups. In an effort to drive business growth , the meeting puts together innovative ICT, Life Sciences and Cleantech companies with investors and innovation experts. In total, 120 companies, which have been selected through the European Venture Contests, will present in this two-days meeting.

Nov 28, 2014

Teresa Tarragó was interviewed at "La Vanguardia", one of the most relevant newspapers with national print run. The document was published on 26th of November. Our CEO explained that she decided to found Iproteos upon the discovery of a drug candidate with interesting applications for the pharmaceutical industry. This final client needs to have the certainty that the compound has minimum risk, and therefore, expensive experiments are required. For that reason, “a molecule has very little value in a basic research laboratory”, Teresa affirms.

Nov 28, 2014

Teresa Tarragó was interviewed by "La Vanguardia", one of the most relevant newspaper and with national print run. In the interview, Teresa explained why she decided to fund Iproteos, upon the identification of a potential drug.